Oramed Pharmaceuticals Inc.ORMP
Price (close)
$4.79
Market cap
$197.9M
P/E
1.1x
Revenue (TTM)
$2.0M
Net income
$174.9M
Dividend yield
5.22%
1-year total return
114.1%
Net margin
—
Revenue growth
—
Debt / equity
—
What Oramed Pharmaceuticals Inc. does.
engaged in the research and development of innovative pharmaceutical solutions with a technology platform that allows for the oral delivery
of therapeutic proteins. In addition, we allocate capital to strategic investments in healthcare and life sciences companies that we
dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $2.7M | $1.3M | — | $2.0M |
| Net income | — | — | -$36.6M | $5.1M | -$19.1M | $64.0M |
| Free cash flow | — | — | -$28.4M | -$10.5M | -$8.4M | -$9.2M |
More on ORMP.
- Oramed Pharmaceuticals Inc. summary
- Oramed Pharmaceuticals Inc. financial statements
- Oramed Pharmaceuticals Inc. key metrics
- Oramed Pharmaceuticals Inc. health scores and style box
- Oramed Pharmaceuticals Inc. earnings
- Oramed Pharmaceuticals Inc. dividends
- Oramed Pharmaceuticals Inc. valuation
- Oramed Pharmaceuticals Inc. ownership and insiders
- Oramed Pharmaceuticals Inc. peers
Figures from Oramed Pharmaceuticals Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.